Trial · NCT04603495
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Splenic Response by Central Radiology Reads at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | 141 | Participants | ||
| Number of Participants With Splenic Response by Central Radiology Reads at Week 24 | Placebo + Ruxolitinib (Control Arm) | 76 | Participants | ||
| Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | -15.99 | Standard Error 1.028 | score on a scale | |
| Key Secondary: Absolute Change From Baseline in Total Symptom Score (TSS) at Week 24 | Placebo + Ruxolitinib (Control Arm) | -14.05 | Standard Error 0.986 | score on a scale | |
| Key Secondary: Number of Participants With TSS50 Response at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | 112 | Participants | ||
| Key Secondary: Number of Participants With TSS50 Response at Week 24 | Placebo + Ruxolitinib (Control Arm) | 100 | Participants | ||
| Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | -50.3 | 95% Confidence Interval -56.6 to -44.0 | Percent change from baseline to Week 24 | |
| Percent Change From Baseline in Total Symptom Score (TSS) at Week 24 | Placebo + Ruxolitinib (Control Arm) | -45.9 | 95% Confidence Interval -51.8 to -40.0 | Percent change from baseline to Week 24 | |
| Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | 36 | Participants | ||
| Number of Participants With Improvement From Baseline in Bone Marrow Fibrosis of at Least 1 Grade at Week 24 | Placebo + Ruxolitinib (Control Arm) | 21 | Participants | ||
| Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment | Pelabresib + Ruxolitinib (Experimental Arm) | 1.359 | 95% Confidence Interval 0.982 to 1.736 | RBC units transfused/patient-months | |
| Rate of Red Blood Cell (RBC) Transfusion Over First 24 Weeks of Treatment | Placebo + Ruxolitinib (Control Arm) | 1.014 | 95% Confidence Interval 0.840 to 1.188 | RBC units transfused/patient-months | |
| Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence | Pelabresib + Ruxolitinib (Experimental Arm) | 0 | Participants | ||
| Number of Participants Who Transitioned From Red Blood Cell (RBC) Transfusion Dependence to Transfusion Independence | Placebo + Ruxolitinib (Control Arm) | 0 | Participants | ||
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | Very much improved | 24 | Participants | |
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Placebo + Ruxolitinib (Control Arm) | Very much improved | 26 | Participants | |
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | Much improved | 63 | Participants | |
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Placebo + Ruxolitinib (Control Arm) | Much improved | 62 | Participants | |
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Pelabresib + Ruxolitinib (Experimental Arm) | Minimally improved | 63 | Participants | |
| Category Change From Baseline of Patient Global Impression of Change (PGIC) at Week 24 | Placebo + Ruxolitinib (Control Arm) | Minimally improved | 79 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04603495/results